Search

Your search keyword '"Mahe, Emmanuel"' showing total 111 results
Start Over Author "Mahe, Emmanuel"
111 results on '"Mahe, Emmanuel"'

3. Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General Population

Author

Plaquevent, Marthe, Tétart, Florence, Fardet, Laurence, Ingen-Housz-Oro, Saskia, Valeyrie-Allanore, Laurence, Bernard, Philippe, Hebert, Vivien, Roussel, Aude, Avenel-Audran, Martine, Chaby, Guillaume, D’Incan, Michel, Ferrier-Le-Bouedec, Marie-Christine, Duvert-Lehembre, Sophie, Picard-Dahan, Catherine, Jeudy, Geraldine, Collet, Evelyne, Labeille, Bruno, Morice, Cécile, Richard, Marie-Aleth, Bourgault-Villada, Isabelle, Litrowski, Noémie, Bara, Corina, Mahe, Emmanuel, Prost-Squarcioni, Catherine, Alexandre, Marina, Quereux, Gaelle, Bernier, Claire, Soria, Angèle, Thomas-Beaulieu, Domitille, Pauwels, Christine, Dereure, Olivier, Benichou, Jacques, and Joly, Pascal

Published
2019
Full Text
View/download PDF

7. Development of monoclonal gammopathy under biotherapy in psoriasis: a French multicenter retrospective study

Author

Liegeon, Anne-Laure, Mahe, Emmanuel, Begon, Edouard, Poreaux, Claire, Barbaud, Annick, Esteve, Eric, Quiles-Tsimaratos, Nathalie, Avenel-Audran, Martine, Schoeffler, Amélie, Mery-Bossard, Laure, Pauwels, Christine, Girard, Céline, Maillard, Hervé, Barthelme, Dominique, Bernier, Claire, Chaby, Guillaume, Reguiai, Ziad, Nguyen-Thi, Phi Linh, Maccari, François, and Schmutz, Jean-Luc

Published
2016
Full Text
View/download PDF

8. Artistic Deviance and Innovation in Use

Author

Mahé, Emmanuel, Harper, Richard, editor, Diaper, Dan, editor, Sanger, Colston, editor, Aldrich, Frances, editor, Bannon, Liam, editor, Boudourides, Moses, editor, Button, Graham, editor, Dewan, Prasun, editor, Grudin, Jonathan, editor, Helgeson, Bo, editor, Hughes, John, editor, Nakata, Keiichi, editor, Palen, Leysia, editor, Randall, David, editor, Schmidt, Kjeld, editor, Sellen, Abigail, editor, Rogers, Yvonne, editor, Haddon, Leslie, editor, Mante, Enid, editor, Sapio, Bartolomeo, editor, Kommonen, Kari-Hans, editor, Fortunati, Leopoldina, editor, and Kant, Annevi, editor

Published
2005
Full Text
View/download PDF

9. Risk factors of progression from discoid lupus to severe systemic lupus erythematosus: a registry-based cohort study of 164 patients.

Author

Fredeau, Lisa, primary, Courvoisier, Delphine S., additional, Ait Mehdi, Raphael, additional, Ingen-Housz-Oro, Saskia, additional, Mahe, Emmanuel, additional, Costedoat-Chalumeau, Nathalie, additional, Arnaud, Laurent, additional, Francès, Camille, additional, Mathian, Alexis, additional, Jachiet, Marie, additional, Amoura, Zahir, additional, Bouaziz, Jean David, additional, and Chasset, François, additional

Published
2022
Full Text
View/download PDF

12. Risk factors of progression from discoid lupus to severe systemic lupus erythematosus: a registry-based cohort study of 164 patients.

Author

Fredeau, Lisa, Courvoisier, Delphine S., Ait Mehdi, Raphael, Ingen-Housz-Oro, Saskia, Mahe, Emmanuel, Costedoat-Chalumeau, Nathalie, Arnaud, Laurent, Francès, Camille, Mathian, Alexis, Jachiet, Marie, Amoura, Zahir, Bouaziz, Jean David, and Chasset, François

Abstract

No study has assessed the risk factors of progression from discoid lupus erythematosus (DLE) to severe systemic lupus erythematosus (sSLE) (defined as requiring hospitalization and specific treatment). To identify the risks factors of and generate a predicting score for progression to sSLE among patients with isolated DLE or associated with systemic lupus erythematosus with mild biological abnormalities. In this registry-based cohort study, multivariable analysis was performed using risk factors identified from literature and pruned by backward selection to identify relevant variables. The number of points was weighted proportionally to the odds ratio (OR). We included 30 patients with DLE who developed sSLE and 134 patients who did not. In multivariable analysis, among 12 selected variables, an age of <25 years at the time of DLE diagnosis (OR, 2.8; 95% CI, 1.1-7.0; 1 point), phototype V to VI (OR, 2.7; 95% CI, 1.1-7.0; 1 point), and antinuclear antibody titers of ≥1:320 (OR, 15; 95% CI, 3.3-67.3; 5 points) were selected to generate the score. Among the 54 patients with a score of 0 at baseline, none progressed to sSLE, whereas a score of ≥6 was associated with a risk of approximately 40%. Retrospective design. In our cohort, an age of <25 years at the time of DLE diagnosis, phototype V to VI, and antinuclear antibody titers of ≥1:320 were risk factors for developing sSLE. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

14. Recours aux médecines alternatives chez les patients adultes atteints de dermatite atopique – Cohorte Daphné

Author

Jacobzone Leveque, Caroline, primary, Reguiai, Ziad, additional, Fougerousse, Anne-Claire, additional, Maccari, François, additional, Badaoui, Antoine, additional, Esteve, Eric, additional, Perrot, Jean Luc, additional, Beaulieu, Domitille Thomas, additional, Begon, Edouard, additional, Delaunay, Juliette, additional, Pillette Delarue, Michelle, additional, Jouan, Nicole, additional, Jachiet, Marie, additional, Pallure, Valérie, additional, Beneton, Nathalie, additional, Parier, Josiane, additional, Misery, Laurent, additional, Fite, Charlotte, additional, and Mahe, Emmanuel, additional

Published
2021
Full Text
View/download PDF

15. Sentiments de culpabilité chez les parents d’enfants atteints de dermatite atopique

Author

Bursztejn, Anne Claire, primary, Shourick, Jason, additional, Bodemer, Christine, additional, Lasek, Audrey, additional, Mahe, Emmanuel, additional, Merhand, Stéphanie, additional, Sampogna, Francesca, additional, Boralevi, Franck, additional, Ezzedine, Khaled, additional, Taieb, Charles, additional, Barbarot, Sébastien, additional, Mallet, Stéphanie, additional, and Abasq, Claire, additional

Published
2021
Full Text
View/download PDF

16. Tolérance et efficacité du traitement du psoriasis par biothérapies ou aprémilast en cas d’antécédent d’hémopathie maligne : étude multicentrique rétrospective

Author

Cohen-Sors, Raphaella, primary, Chaby, Guillaume, additional, Fougerousse, Anne-Claire, additional, Maccari, François, additional, Roussel, Aude, additional, Reguiai, Ziad, additional, Mahe, Emmanuel, additional, Amy de la Breteque, Maud, additional, Delaunay, Juliette, additional, Cottencin, Anne-Caroline, additional, Bertolotti, Antoine, additional, and Kemp, Helene, additional

Published
2021
Full Text
View/download PDF

18. Description de la dermatite atopique de l’adulte, résultats de la cohorte DAPHNE

Author

Leveque, Caroline Jacobzone, primary, Reguiai, Ziad, additional, Fougerousse, Anne Claire, additional, Maccari, Francois, additional, Badaoui, Antoine, additional, Esteve, Eric, additional, Perrot, Jean Luc, additional, Beaulieu, Domitille Thomas, additional, Begon, Edouard, additional, Delaunay, Juliette, additional, Delarue, Michelle Pillette, additional, Jouan, Nicole, additional, Jachiet, Marie, additional, Pallure, Valérie, additional, Beneton, Nathalie, additional, Parier, Josiane, additional, Misery, Laurent, additional, Fite, Charlotte, additional, Henry, Catherine Goujon, additional, Danic, Dominique Lons, additional, Bourrel, Magali, additional, Mery, Laure, additional, Abasq, Claire, additional, Salins, Claire Alice de, additional, Lepelley, Charlotte, additional, and Mahe, Emmanuel, additional

Published
2021
Full Text
View/download PDF

19. Perception de la sévérité clinique de la dermatite atopique chez l’enfant : comparaison entre l’évaluation des patients et celle des parents

Author

Mahe, Emmanuel, primary, Shourick, Jason, additional, Bursztejn, Anne Claire, additional, Bodemer, Christine, additional, Lasek, Audrey, additional, Merhand, Stéphanie, additional, Sampogna, Francesca, additional, Boralevi, Franck, additional, Barbarot, Sébastien, additional, Mallet, Stéphanie, additional, Abasq, Claire, additional, Taieb, Charles, additional, and Ezzedine, Khaled, additional

Published
2021
Full Text
View/download PDF

20. Dermatite atopique du sujet âgé. Cohorte Daphné

Author

Leveque, Caroline Jacobzone, primary, Reguiai, Ziad, additional, Fougerousse, Anne-Claire, additional, Maccari, François, additional, Badaoui, Antoine, additional, Esteve, Eric, additional, Perrot, Jean Luc, additional, Beaulieu, Domitille Thomas, additional, Begon, Edouard, additional, Delaunay, Juliette, additional, Delarue, Michelle Pillette, additional, Jouan, Nicole, additional, Jachiet, Marie, additional, Pallure, Valérie, additional, Beneton, Nathalie, additional, Parier, Josiane, additional, Fite, Charlotte, additional, Mery, Laure, additional, Abasq, Claire, additional, and Mahe, Emmanuel, additional

Published
2021
Full Text
View/download PDF

21. Dermatite atopique de l’adulte à type de prurigo – données de la cohorte Daphné

Author

Jacobzone Leveque, Caroline, primary, Reguiai, Ziad, additional, Fougerousse, Anne-Claire, additional, Maccari, François, additional, Badaoui, Antoine, additional, Esteve, Eric, additional, Perrot, Jean Luc, additional, Beaulieu, Domitille Thomas, additional, Begon, Edouard, additional, Delaunay, Juliette, additional, Pillette Delarue, Michelle, additional, Jouan, Nicole, additional, Jachiet, Marie, additional, Pallure, Valérie, additional, Beneton, Nathalie, additional, Parier, Josiane, additional, Misery, Laurent, additional, Fite, Charlotte, additional, Goujon Henry, Catherine, additional, Lons Danic, Dominique, additional, and Mahe, Emmanuel, additional

Published
2021
Full Text
View/download PDF

22. Onset and Relapse of Juvenile Dermatomyositis Following Asymptomatic SARS-CoV-2 Infection

Author

Rodero, Mathieu Paul, Pelleau, Stéphane, Welfringer-Morin, Anne, Duffy, Darragh, Melki, Isabelle, Bader-Meunier, Brigitte, Bondet, Vincent, Gitiaux, Cyril, Bonigen, Julie, Fayand, Antoine, Courdavault Vagh Weinmann, Laurence, Mahe, Emmanuel, Charuel, Jean Luc, Alyanakian, Marie-Alexandra, Herbeuval, Jean Philippe, White, Michael, Rodero, Mathieu, Évaluer l'immunité contre SARS-CoV-2 à l'échelle de la population grâce aux tests sérologiques - - CorPopImm2020 - ANR-20-COVI-0052 - COVID-19 - VALID, Variation de la réponse immune systémique et muqueuse pendant l'infection par le SRAS-CoV-2 et la convalescence - - CoVarImm2020 - ANR-20-COVI-0053 - COVID-19 - VALID, Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques (LCBPT - UMR 8601), Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Epidémiologie et Analyse des Maladies Infectieuses - Infectious Disease Epidemiology and Analytics, Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Immunologie Translationnelle - Translational Immunology lab, Laboratory of neurogenetics and neuroinflammation (Equipe Inserm U1163), Imagine - Institut des maladies génétiques (IHU) (Imagine - U1163), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Centre de référence des rhumatismes inflammatoires et maladies autoimmunes systémiques rares de l'enfant [Paris] (RAISE), AP-HP Hôpital universitaire Robert-Debré [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'immuno-hématologie pédiatrique [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Immunogenetics of pediatric autoimmune diseases (Equipe Inserm U1163), Service de Médecine Interne = Hôpital de jour de médecine [CHU Tenon], CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Victor Dupouy, CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), DD was supported by the Agence Nationale de la Recherche as part of the Flash Covid funding (CoVarImm). MW was supported by the Agence Nationale de la Recherche and Fondation pour la Recherche Médicale (CorPopImm)., FJDM study group, ANR-20-COVI-0052,CorPopImm,Évaluer l'immunité contre SARS-CoV-2 à l'échelle de la population grâce aux tests sérologiques(2020), ANR-20-COVI-0053,CoVarImm,Variation de la réponse immune systémique et muqueuse pendant l'infection par le SRAS-CoV-2 et la convalescence(2020), Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), Institut Pasteur [Paris], Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Service de Médecine Interne [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Hôpital Robert Debré, and FJDM Study group Vincent Bondet, Cyril Gitiaux, Julie Bonigen, Antoine Fayand, Laurence Courdavault Vagh Weinmann, Emmanuel Mahe, Jean Luc Charuel, Marie-Alexandra Alyanakian, Jean Philippe Herbeuva, Michael White

Subjects
030203 arthritis & rheumatology, 0303 health sciences, medicine.medical_specialty, 2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), [SDV]Life Sciences [q-bio], Immunology, medicine.disease, Letter to Editor, Virology, Asymptomatic, 3. Good health, [SDV] Life Sciences [q-bio], 03 medical and health sciences, 0302 clinical medicine, Medical microbiology, Immunology and Allergy, Medicine, medicine.symptom, business, Juvenile dermatomyositis, ComputingMilieux_MISCELLANEOUS, 030304 developmental biology
Abstract

International audience; No abstract available

Published
2021
Full Text
View/download PDF

23. Mechanism of action and clinical benefits of colloidal oatmeal for dermatologic practice

Author

Cerio, Rino, Dohil, Magdalene, Downie, Jeanine, Magina, Sofia, Mahe, Emmanuel, and Stratigos, Alexander J.

Subjects
Skin diseases -- Care and treatment, Skin diseases -- Patient outcomes, Dermatologic agents -- Dosage and administration, Dermatologic agents -- Patient outcomes, Dermatology -- Formulae, receipts, prescriptions, Dermatology -- Dosage and administration, Dermatology -- Patient outcomes, Health, Pharmaceuticals and cosmetics industries
Abstract

ABSTRACT Colloidal oatmeal has a long history of beneficial use in dermatology. It is a natural product that has an excellent safety record and has demonstrated efficacy for the treatment [...]

Published
2010

24. Perialar intertrigo in children and adolescents: A multicenter prospective study of 41 cases.

Author

Sanchez, Adrien, Mahe, Emmanuel, Miquel, Juliette, Abasq, Claire, Phan, Alice, Mazereeuw‐Hautier, Juliette, Lemille, Juliette, Maruani, Annabel, Bonniaud, Bertille, Plantin, Patrice, Mallet, Stéphanie, Martin, Hélène, Hubiche, Thomas, Chiaverini, Christine, and Lacour, Jean‐Philippe

Subjects
*LONGITUDINAL method, *TEENAGERS, *SYMPTOMS, *ROSACEA, *SEBORRHEIC dermatitis, *COHORT analysis
Abstract

Background/Objectives: We observed isolated cases of perialar intertrigo in children and teenagers that did not appear to correspond to any known clinical entity. The objective of this study was to describe the clinical features of this dermatosis and the clinical characteristics of the patients. Methods: We conducted a prospective, multicenter cohort study in France from August 2017 to November 2019. All the patients under 18 years of age with chronic perinasal intertrigo were included. A standardized questionnaire detailing the clinical characteristics of the patients and the description of the intertrigo. If possible, a Wood's lamp examination of the intertrigo was done. Results: Forty‐one patients were included (25 boys and 16 girls, average age: 12.1 years). Intertrigo was bilateral in 38 patients (93%). The majority of patients had no symptoms (54%). Pruritus was present in 39% of cases. Orange red follicular fluorescence was present in the perialar region on Wood's light examination in 78% of cases with active fluorescence. The presumptive diagnoses suggested by the investigators were acne (24.4%), seborrheic dermatitis (19.5%), rosacea (9.8%), psoriasis (9.8%) and perioral dermatitis (7.3%). No diagnosis was proposed in 22% of the cases. Conclusions: We describe a previously undescribed clinical sign which is characterized by a chronic bilateral erythematous intertrigo located in the perialar region. It can be isolated or associated with various facial dermatoses. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

25. A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents

Author

Bronckers, Inge M. G. J. Paller, Amy S. West, Dennis P. and Lara-Corrales, Irene Tollefson, Megha M. Tom, Wynnis L. and Hogeling, Marcia Belazarian, Leah Zachariae, Claus Mahe, Emmanuel Siegfried, Elaine Blume-Peytavi, Ulrike Szalai, Zsuzsanna Vleugels, Ruth Ann Holland, Kristen Murphy, Ruth and Puig, Lluis Cordoro, Kelly M. Lambert, Jo Alexopoulos, Alex Mrowietz, Ulrich Kievit, Wietske Seyger, Marieke M. B. and Psoriasis Investigator Grp Pediat Dermatology Res Alliance and European Working Grp Pediat

Abstract

This cohort study compares the use of methotrexate vs biologic agents in children with moderate to severe psoriasis. Question What is the association between use of methotrexate vs biologics and psoriasis severity and drug survival (rate and duration of adherence to a specific drug regimen) in pediatric patients with moderate to severe psoriasis? Findings In this cohort study including 234 pediatric patients with moderate to severe psoriasis, those receiving biologics were more likely than those treated with methotrexate to achieve a Physician Global Assessment status of clear/almost clear and 75% or more improvement of the Psoriasis Area and Severity Index rating at 6 months. In addition, biologics were associated with better drug survival rates at 1, 3, and 5 years, with comparable discontinuation rates owing to lack of response. Meaning In pediatric patients with psoriasis, treatment with biologics may be associated with a significantly greater reduction in psoriasis severity than methotrexate; nevertheless, with 35.6% of the patients achieving clear/almost clear and 40.0% reaching 75% or more improvement on the Psoriasis Area and Severity Index, methotrexate remains an effective treatment for pediatric psoriasis. Importance Few studies have compared the use of methotrexate and biologics, the most commonly used systemic medications for treatment of moderate to severe psoriasis in children. Objective To assess the real-world, 6-month reduction in psoriasis severity and long-term drug survival (rate and duration of adherence to a specific drug) of methotrexate vs biologics in plaque psoriasis in children. Design, Setting, and Participants A retrospective medical records review was conducted at 20 European and North American centers. Treatment response was based on site-reported Psoriasis Area and Severity Index (PASI) and/or Physician Global Assessment (PGA) scores at baseline and within the first 6 months of treatment. Participants included all 234 consecutively seen children with moderate to severe psoriasis who received at least 3 months of methotrexate or biologics from December 1, 1990, to September 16, 2014, with sufficient data for analysis. Data analysis was performed from December 14, 2015, to September 1, 2016. Main Outcomes and Measures PASI, with a range from 0 to 72 (highest score indicating severe psoriasis), and/or PGA, with a scale of 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), and 5 (very severe). Results Of 234 pediatric patients (103 boys [44.0%]; 131 girls [56.0%]) treated with methotrexate and/or biologics, 163 patients (69.7%) exclusively received methotrexate, 47 patients (20.1%) exclusively received biologics, and 24 children (10.2%) received methotrexate and biologics sequentially. Of the latter cohort, 23 children were treated initially with methotrexate. Mean (SD) age at initiation was 11.6 (3.7) years for methotrexate and 13.3 (2.9) years for biologics (73.2% for etanercept) (P = .002). Among patients evaluated by a scoring method at 6-month follow-up, 75% or greater improvement in PASI (PASI75) was achieved in 12 of 30 patients (40.0%) receiving methotrexate and 20 of 28 patients (71.4%) receiving biologics, and PGA was clear/almost clear (PGA 0/1) in 41 of 115 patients (35.6%) receiving methotrexate and 18 of 37 patients (48.6%) receiving biologics. Achieving PASI75 and/or PGA 0/1 between baseline and 6 months was more likely with biologics than methotrexate (PASI75: odds ratio [OR], 4.56; 95% CI, 2.02-10.27; P < .001; and PGA 0/1: OR, 2.00; 95% CI, 0.98-4.00; P = .06). Decreased mean PASI and PGA scores were associated with biologics more than with methotrexate (PASI effect, -3.13; 95% CI, -4.33 to -1.94; P < .001; and PGA effect, -0.31; 95% CI, -0.56 to -0.06; P = .02). After 1, 3, and 5 years of use, overall drug survival rates for methotrexate were 77.5%, 50.3%, and 35.9%, and for biologics, the rates were 83.4%, 64.3%, and 57.1%, respectively. Biologics were associated with a better confounder-corrected drug survival than methotrexate (hazard ratio [HR], 2.23; 95% CI, 1.21-4.10; P = .01). Discontinuation owing to lack of response was comparable (HR, 1.64; 95% CI, 0.80-3.36; P = .18). Conclusions and Relevance Methotrexate and biologics appear to be associated with improvement in pediatric psoriasis, although biologics seem to be associated with greater reduction in psoriasis severity scores and higher drug survival rates than methotrexate in the real-world setting. Additional studies directly comparing these medications should be performed for confirmation.

Published
2020

27. Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study

Author

Mahil, Satveer K., primary, Dand, Nick, additional, Mason, Kayleigh J., additional, Yiu, Zenas Z.N., additional, Tsakok, Teresa, additional, Meynell, Freya, additional, Coker, Bola, additional, McAteer, Helen, additional, Moorhead, Lucy, additional, Mackenzie, Teena, additional, Rossi, Maria Teresa, additional, Rivera, Raquel, additional, Mahe, Emmanuel, additional, Carugno, Andrea, additional, Magnano, Michela, additional, Rech, Giulia, additional, Balogh, Esther A., additional, Feldman, Steven R., additional, De La Cruz, Claudia, additional, Choon, Siew Eng, additional, Naldi, Luigi, additional, Lambert, Jo, additional, Spuls, Phyllis, additional, Jullien, Denis, additional, Bachelez, Hervé, additional, McMahon, Devon E., additional, Freeman, Esther E., additional, Gisondi, Paolo, additional, Puig, Luis, additional, Warren, Richard B., additional, Di Meglio, Paola, additional, Langan, Sinéad M., additional, Capon, Francesca, additional, Griffiths, Christopher E.M., additional, Barker, Jonathan N., additional, Smith, Catherine H., additional, Shah, Aadarsh, additional, Barea, Alberto, additional, Romero-Maté, Alberto, additional, Singapore, Alekya, additional, Paolino, Alexandra, additional, Mwale, Alice, additional, Morales Callaghan, Ana Maria, additional, Martinez, Ana, additional, DeCrescenzo, Andrew, additional, Pink, Andrew E., additional, Jones, Ann, additional, Sergeant, Ann, additional, Essex, Annette, additional, Bewley, Anthony, additional, Makrygeorgou, Areti, additional, van Huizen, Astrid, additional, Pérez-Suárez, Beatriz, additional, Farida, Benhadou, additional, Claréus, Birgitta Wilson, additional, Prims, Carla Tubau, additional, Davis, Carrie, additional, Quinlan, Catherine, additional, Maybury, Catriona, additional, Cesar, Gonzalez A., additional, Barclay, Charlotte, additional, Greco, Claudio, additional, Brassard, Danielle, additional, Cummings, Deanna, additional, Kolli, Deepti, additional, Descamps, Vincent, additional, Genao, Diana Ruiz, additional, Carras, Efrossini, additional, Hawryluk, Elena, additional, Martínez-García, Eliseo, additional, Klujszo, Elzbieta, additional, Dwyer, Emily, additional, Toni, Emmanuel, additional, Sonkoly, Enikö, additional, Loayza, Enrique, additional, Daudén, Esteban, additional, Valenzuela, Fernando, additional, Popov, Georgi, additional, King, Georgie, additional, Celine, Girard, additional, Aparicio, Gloria, additional, Johnston, Graham A., additional, Cardozo, Gustavo Anibal, additional, Pearson, Ian, additional, Yanguas, Ignacio, additional, Weisman, Jamie, additional, Carolan, Jennifer E., additional, Hughes, Jenny, additional, Ortiz-Salvador, Jose-Maria, additional, Carrascosa, Jose-Manuel, additional, Schwartz, Joseph J., additional, Jackson, Karina, additional, Kerisit, Kathryn G., additional, Wu, Keith, additional, Asfour, Leila, additional, de Graaf, Leontien, additional, Lesort, Cécile, additional, Meuleman, Lieve, additional, Eidsmo, Liv, additional, Skov, Lone, additional, Gribben, Lorraine, additional, Rustin, Malcolm, additional, Velasco, Manel, additional, Panchal, Manisha, additional, Lakhan, Manpreet, additional, Franco, Manuel D., additional, Svensson, Marie-Louise, additional, Vandaele, Mark, additional, Marovt, Maruska, additional, Zargari, Omid, additional, De Caso, Pablo, additional, Varela, Paulo, additional, Jenkin, Peter, additional, Phan, Céline, additional, Hampton, Philip, additional, Goldsmith, Portia, additional, Bak, Rachel, additional, Speeckaert, Reinhart, additional, Romiti, Ricardo, additional, Woolf, Richard, additional, Mercado-Seda, Rogelio, additional, Khatun, Rohima, additional, Ceovic, Romana, additional, Taberner, Rosa, additional, Cohen, Russell W., additional, Stefanescu, Simina, additional, Kirk, Sarah, additional, Reeken, Saskia, additional, Ayob, Shanti, additional, Pérez-Barrio, Silvia, additional, Piaserico, Stefano, additional, Hoey, Susannah, additional, Torres, Tiago, additional, Talme, Toomas, additional, Desai, Trupti V., additional, van Geest, Adrienne J., additional, King, Victoria, additional, Di Lernia, Vito, additional, Koreja, Zahira, additional, and Hasab, Vito Zeeshaan, additional

Published
2021
Full Text
View/download PDF

31. Clinical Profile of Methotrexate-resistant Juvenile Localised Scleroderma

Author

Hardy, Juliette, Boralevi, Franck, Mallet, Stephanie, Cabrera, Natalia, Belot, Alexandre, Phan, Alice, Barbarot, Sébastien, Duriez-Lasek, Audrey, Chiaverini, Christine, Hubiche, Thomas, Mahe, Emmanuel, Begon, Edouard, Bourrat, Emmanuelle, Boccara, Olivia, Aubert, Hélène, Lerosey, Martine Grall, Droitcourt, Catherine, Piram, Maryam, Mazereeuw-Hautier, Juliette, Research Group of the French Society of Paediatric Dermatology (SDFP in French), ., Hôpital Larrey [Toulouse], CHU Toulouse [Toulouse], Université de Bordeaux (UB), Hôpital de la Timone [CHU - APHM] (TIMONE), Hôpital Femme Mère Enfant, Hôpital Hôtel-Dieu [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Saint-Vincent de Paul, Centre Hospitalier Universitaire de Nice (CHU Nice), Centre Hospitalier Intercommunal, Hôpital d'Argenteuil, Université de Cergy Pontoise (UCP), Université Paris-Seine, AP-HP Hôpital universitaire Robert-Debré [Paris], CHU Necker - Enfants Malades [AP-HP], CHU Rouen, Normandie Université (NU), CHU Pontchaillou [Rennes], AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), and Hardy, Juliette

Subjects
0301 basic medicine, Male, medicine.medical_specialty, Adolescent, morphea, Drug Resistance, Médecine humaine et pathologie, Dermatology, Scleroderma, 03 medical and health sciences, Localised scleroderma, Scleroderma, Localized, 0302 clinical medicine, Internal medicine, lcsh:Dermatology, medicine, Juvenile, Humans, scleroderma, Localized Scleroderma, Paediatric dermatology, Child, Retrospective Studies, Dermatologie, 030203 arthritis & rheumatology, localized scleroderma, methotrexate, treatment, business.industry, Infant, General Medicine, lcsh:RL1-803, medicine.disease, Rheumatology, 3. Good health, 030104 developmental biology, Methotrexate, Child, Preschool, Human health and pathology, Female, Dermatologic Agents, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology, Morphea, medicine.drug
Abstract

International audience; Methotrexate has demonstrated its efficiency for the treatment of juvenile localized scleroderma but some patients may be resistant. The aim of our study was to define the profile of such patients. We performed an observational retrospective multicenter study between 2007 and 2016 and included all children seen in the French Paediatric Dermatology and Rheumatology departments with active localized scleroderma treated by methotrexate for a minimum of 4 months. Metho-trexate efficacy was assessed clinically and/or by imaging between the fourth to twelfth months of treatment. A total of 57 patients were included. Metho-trexate dosage ranged from 7 to 15 mg/m2/week. Only 4 patients were resistant. No common features could be identified between these 4 patients. Children with localized scleroderma are rarely resistant to metho-trexate and we did not identify a clinical profile for those resistant patients.

Published
2019
Full Text
View/download PDF

33. Efficacité et tolérance du dupilumab dans le traitement de la dermatite atopique de l’enfant de moins de 12 ans en vie courante : cohorte rétrospective multicentrique française

Author

Lasek, Audrey, Bellon, Nathalia, Mallet, Stéphanie, Puzenat, Eve, Bursztejn, Anne Claire, Abasq, Claire, Mazereeuw, Juliette, Chiaverini, Christine, Hubiche, Thomas, Peyron, Nadia Raison, Du Thanh, Aurélie, Barbarot, Sébastien, Aubert, Hélène, Reguiai, Ziad, Droitcourt, Catherine, Fievet, Charlotte, Bellissen, Astrid, Bachelerie, Marie, Nosbaum, Audrey, Leymarie, Alicia, Armingaud, Pierre, and Mahé, Emmanuel

Published
2021
Full Text
View/download PDF

34. Tolérance des biothérapies et de l’aprémilast pour un psoriasis chez des patients avec antécédent de cancer solide : étude rétrospective multicentrique

Author

Fougerousse, Anne-Claire, Failla, Valérie, Mahé, Emmanuel, Chaby, Guillaume, Maccari, François, Perrot, Jean-Luc, Boulard, Claire, Brenaut, Emilie, Ghislain, Pierre-Dominique, Girard, Céline, Becherel, Pierre-André, Lepelley-Dupont, Charlotte, Parier, Josiane, Quiles, Nathalie, Begon, Edouard, Dillies, Anne-Sophie, Florin, Valérie, Jacobzone, Caroline, Osdoit, Sophie, Samimi, Mahtab, Maillard, Hervé, and Mery-Bossard, Laure

Published
2021
Full Text
View/download PDF

39. Biomédicaments dans le psoriasis de l’enfant de moins de 12 ans. Cohorte rétrospective Franco-Italienne

Author

Zitouni, Jinane, Beauchet, Alain, Di Lernia, Vito, Bursztejn, Anne-Claire, Mazereeuw-Hautier, Juliette, Gottlieb, Jérémy, Lasek, Audrey, Aubert, Hélène, Barbarot, Sébastien, Droitcourt, Catherine, Bulai-Livideanu, Cristina, Fortina, Anna Belloni, Caroppo, Francesca, Quiles-Tsimaratos, Nathalie, Mallet, Stéphanie, Barthélémy, Hugues, Puzenat, Eve, Bouilly-Auvray, Danielle, Phan, Céline, and Mahé, Emmanuel

Published
2021
Full Text
View/download PDF

44. Nécrobiose lipoïdique : 33 cas

Author

Tella, Emilie, Jacquin, Aurélien, Maillard, Hervé, Senet, Patricia, Kottler, Diane, Goujon, Elisa, Modiano, Philippe, Le Guern, Aurore, Lok, Catherine, and Mahé, Emmanuel

Published
2021
Full Text
View/download PDF

45. Changements (« switchs ») de biothérapies dans le psoriasis de l’enfant : résultats de la cohorte BiPe

Author

Phan, Céline, Beauchet, Alain, reguiai, Ziad, Severino-Freire, Maëlla, Mazereeuw-Hautier, Juliette, Bursztejn, Anne Claire, Barbarot, Sébastien, Hadj-Rabia, Smaïl, Girard, Céline, Phan, Alice, Lacour, Jean Philippe, Lasek, Audrey, Brenaut, Emilie, Perrussel, Marc, Mallet, Stéphanie, Piram, Maryam, Fougerousse, Anne-Claire, Barthélémy, Hugues, Balguérie, Xavier, and Mahé, Emmanuel

Published
2021
Full Text
View/download PDF

47. Onset and Relapse of Juvenile Dermatomyositis Following Asymptomatic SARS-CoV-2 Infection.

Author

Rodero, Mathieu Paul, Pelleau, Stéphane, Welfringer-Morin, Anne, Duffy, Darragh, Melki, Isabelle, Bader-Meunier, Brigitte, FJDM Study group, Bondet, Vincent, Gitiaux, Cyril, Bonigen, Julie, Fayand, Antoine, Weinmann, Laurence Courdavault Vagh, Mahe, Emmanuel, Charuel, Jean Luc, Alyanakian, Marie-Alexandra, Herbeuva, Jean Philippe, and White, Michael

Subjects
JUVENILE diseases, SARS-CoV-2, DERMATOMYOSITIS, INFECTION, NEUROMUSCULAR diseases
Abstract

Dear Editor, SARS-CoV-2 infection drives a marked inflammation and has been described to precede the appearance in rare occasion of various autoimmune and inflammatory diseases including clinical, radiological, muscle biopsy, and serological features consistent with dermatomyositis [[1]]. Altogether, out of the 10 patients with onset or relapse of JDM features seen in our center between April 2020 and March 2021, we identified 2 (20%) with a concomitant history of SARS-CoV-2 infection. [Extracted from the article]

Published
2022
Full Text
View/download PDF

48. Efficacy and tolerance of dupilumab in patients with moderate‐to‐severe atopic dermatitis and obesity.

Author

Dupuis, Joséphine, Tauber, Marie, Mahe, Emmanuel, Jachiet, Marie, Soria, Angèle, Tetart, Florence, Puzenat, Eve, Pasteur, Justine, Raison‐Peyron, Nadia, Giordano‐Labadie, Françoise, Droitcourt, Catherine, Leleu, Camille, Nosbaum, Audrey, Aubert, Hélène, Moigne, Marie L. E., Bernier, Claire, Barbarot, Sébastien, Ezzedine, Khaled, Diaz, Emmanuelle, and Hubiche, Thomas

Subjects
*MAJOR adverse cardiovascular events, *CLINICAL drug trials, *BODY mass index, *FISHER exact test, *SEBORRHEIC dermatitis
Abstract

This article discusses a study on the drug dupilumab and its effectiveness in treating atopic dermatitis (AD) in obese patients. The study found that dupilumab was effective in treating AD in obese patients, although the response rate was slightly lower compared to non-obese patients. The study also observed weight changes in both groups, with some patients experiencing weight gain and others experiencing weight loss. The authors recommend weight monitoring during treatment and suggest that optimized dosages may be considered for obese patients. The study was supported by the FRADEN/F-CRIN network and the authors disclose potential conflicts of interest. This document is a letter to the editor written by dermatologists and researchers from various hospitals and institutions in France. The letter discusses the potential factors influencing dupilumab response, the impact of body mass index on treatment outcomes, and weight gain in patients receiving dupilumab. The study was approved by an ethics committee and the data supporting the findings are available upon request. [Extracted from the article]

Published
2024
Full Text
View/download PDF

49. Pédiatrie (2° Éd.) (collection Le livre de l'interne)

Author

BENOIST Grégoire, MAHÉ Emmanuel, CHEVALLIER Bertrand, BENOIST Grégoire, MAHÉ Emmanuel, and CHEVALLIER Bertrand

Abstract

La deuxième édition du Livre de l'interne en pédiatrie a été entièrement actualisée pour accompagner au mieux le médecin. Elle comprend les dernières recommandations ainsi que des travaux récents présentant les stratégies diagnostiques ou thérapeutiques. Les auteurs ont choisi les situations les plus fréquentes en privilégiant la pratique : l'examen clinique, les prescriptions d'examens complémentaires et les principaux traitements proposés. L'ensemble des chapitres de ce livre est construit sur un même modèle. La démarche est descriptive, puis analytique. Les points essentiels sont soulignés en début de chapitre, tandis que les tableaux et les arbres décisionnels forment une synthèse visuelle claire. L'ouvrage recouvre l'ensemble des spécialités d'organes concernant l'enfant, depuis la naissance jusqu'au passage de l'adolescence à l'âge adulte. Les 71 chapitres sont répartis en 12 grandes parties : adolescent, cardiologie – hémodynamique, chirurgie, dermatologie, endocrinologie, gastroentérologie, hématologie, maladies infectieuses, néphrologie, neurologie, ORL – ophtalmologie, pneumologie.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results